IP Library Granted Patent US 12,060,418
Granted Patent B2
US 12,060,418 · App. 16/389,356 · Granted Aug 13, 2024

Bispecific IgG antibodies as T cell engagers

Inventors: Alexander Berthold Hendrik Bakker (Utrecht, NL); Pieter Fokko Van Loo (Utrecht, NL); Ton Logtenberg (Utrecht, NL)
Assignee: Merus N.V.
C07K16/28C07K16/2809C07K16/2851C07K16/3061A61K2039/505C07K2317/21C07K2317/31C07K2317/526C07K2317/53C07K2317/55C07K2317/569C07K2317/70C07K2317/71C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,060,418
App. No.
16/389,356
Granted
Aug 13, 2024
Kind
B2
Abstract

Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.

Claims (13)

1. A CLEC12A binding domain comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises;

i) a heavy chain CDR1 comprising the amino acid sequence SGYTFTSY (SEQ ID NO: 1), a heavy chain CDR2 comprising the amino acid sequence IINPSGGS (SEQ ID NO: 2), and a heavy chain CDR3 comprising the amino acid sequence GTTGDWFDY (SEQ ID NO: 3),

ii) a heavy chain CDR1 comprising the amino acid sequence SGYTFTSY (SEQ ID NO: 5), a heavy chain CDR2 comprising the amino acid sequence IINPSGGS (SEQ ID NO: 6), and a heavy chain CDR3 comprising the amino acid sequence GNYGDEFDY (SEQ ID NO: 7); or

iii) a heavy chain CDR1 comprising the amino acid sequence SGYTFTGY (SEQ ID NO: 9), a heavy chain CDR2 comprising the amino acid sequence WINPNSGG (SEQ ID NO: 10), and a heavy chain CDR3 comprising the amino acid sequence DGYFADAFDY (SEQ ID NO: 11),

and wherein the light chain variable region comprises a light chain CDR1 comprising the amino acid sequence RASQSISSYLN (SEQ ID NO: 17), a light chain CDR2 sequence comprising the amino acid sequence AASSLQS (SEQ ID NO: 18), and a light chain CDR3 sequence comprising the amino acid sequence QQSYSTPPT (SEQ ID NO: 19).

2. The CLEC12A binding domain of claim 1 , wherein the light chain variable region comprises human kappa light chain Ig Vκ1-39*01/IGJκ1*01.

3. The CLEC12A binding domain of claim 1 , wherein the light chain variable region comprises an amino acid sequence that is at least 90% identical to DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFS GSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK (SEQ ID NO: 20).

4. The CLEC12A binding domain of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTS YAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGTLVTVSS (SEQ ID NO: 4).

5. The CLEC12A binding domain of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTS YAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGNYGDEFDYWGQGTLVTVSS (SEQ ID NO: 8).

6. The CLEC12A binding domain of claim 1 , wherein the heavy chain variable comprises an amino acid sequence that is at least 90% identical to QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGT NYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDGYFADAFDYWGQGTLVTV SS (SEQ ID NO: 12).

7. The CLEC12A binding domain of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 20.

8. The CLEC12A binding domain of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 8 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 20.

9. The CLEC12A binding domain of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12 and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 20.

Assignments (5)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jan 30, 2026
From: MERUS B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074562/0322 →
SECURITY INTEREST Recorded Jan 29, 2026
From: MERUS B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 074532/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2020
From: BAKKER, ALEXANDER BERTHOLD HENDRIK; VAN LOO, PIETER FOKKO; LOGTENBERG, TON
To: MERUS B.V.
Reel/Frame 053741/0804 →
CHANGE OF ADDRESS Recorded Sep 11, 2020
From: MERUS N.V.
To: MERUS N.V.
Reel/Frame 053755/0043 →
CHANGE OF NAME Recorded Sep 11, 2020
From: MERUS B.V.
To: MERUS N.V.
Reel/Frame 053757/0444 →
Continuity (4)
Division 14040023 · Sep 27, 2013
Provisional Application 61834915 · Jun 14, 2013
Provisional Application 61706543 · Sep 27, 2012
Related Publication 20190352393A1 · Nov 21, 2019